No disclosed relationships extracted for GHRSyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trial and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate, and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
No earnings record for GHRS on the current feed.
Nothing on the wire mentions GHRS yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How GHRS has moved on past release days vs its typical ±3.5% day, and how often it closed up. Computed from daily closes — not a forecast.